Comparison of Caveolin-1 and PSA in Prostate Adenocarcinoma

Objective & Hypothesis:Objective: The aim of the present study was to evaluate caveolin-1 (CAV-1) levels as a possible alternative for the prostate specific antigen in the diagnosis of patients with prostate adenocarcinoma (PCa).Methods: The study was conducted with 33 cases (mean age 67.2 (45-90) years) and 16 control patients (mean age 56.68 (48-77) years).

📊

Key Findings & Data:Blood sample solution results of both the groups were read twice, and the average optical density of the zero standard was subtracted from the solution results’ average.Results: The average levels of prostate-specific antigen (PSA) were 1.1 (±0.64) for the control group and 12.3 (±8.7) for patients with adenocarcinoma.

💡

Conclusion & Impact:Patients with PCa had higher PSA and CAV-1 than the control group (p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the present study was to evaluate caveolin-1 (CAV-1) levels as a possible alternative for the prostate specific antigen in the diagnosis of patients with prostate adenocarcinoma (PCa).Methods: The study was conducted with 33 cases (mean age 67.2 (45-90) years) and 16 control patients (mean age 56.68 (48-77) years). Blood sample solution results of both the groups were read twice, and the average optical density of the zero standard was subtracted from the solution results’ average.Results: The average levels of prostate-specific antigen (PSA) were 1.1 (±0.64) for the control group and 12.3 (±8.7) for patients with adenocarcinoma. The average levels of CAV-1 were 336 (±41.1) in the control group and 476 (±66.9) in patients with adenocarcinoma. PCa was detected in 33 patients, 27 of whom underwent prostatectomy, and the remaining 6 began hormonotherapy. Of these 33 patients, 2 had a Gleason score of 4, 16 had a Gleason score of 6, 10 had a Gleason score of 7, 3 had a Gleason score of 8, and 2 had a Gleason score of 9. Patients with PCa had higher PSA and CAV-1 than the control group (p

Özet

Amaç: Bu çalışmanın amacı prostat adenokarsinomu (PCa) olan hastaların tanısında prostat spesifik antijen (PSA) için olası bir alternatif olarak Caveolin-1 (CAV-1) seviyelerini değerlendirmektir. Yöntemler: Çalışma 33 hasta ve 16 kontrol grubu olmak üzere iki gruba ayrılmıştır. Her iki grubun kan örneklerinden ELİSA kiti ile CAV-1 düzeyleri çalışıldı. Sonuçlar tanı öncesi PSA düzeyi ile karşılaştırılarak istatistiksel olarak analiz edildi. Bulgular: Çalışmada hasta grubunun yaş ortalaması 67,2 (45-90) iken kontrol grubunu ortalama yaşı 56,68 (48-77) idi. PSA ortalaması kontrol grubu için 1,1 (±0,64), adenokarsinomalı hastalar için 12,3 (±8,7) idi. Kontrol grubunda ortalama CAV-1 düzeyi 336 (±41,1), adenokarsinomalı hastalarda ise 476 (±66,9) idi. Hastaların 27'sine prostatektomi yapıldı, geriye kalan 6'sına ise hormonoterapiye başlandı. Bu 33 hastadan 18’inin Gleason Skoru (GS) 6 ve altında, 10'u GS 7, 3'ünün GS 8 ve 2'si GS 9 idi. Prostat adenokarsinomu olan grupta daha yüksek PSA ve CAV-1 düzeyleri saptandı (p

🔖

Cite This Article

TAŞ, T., ONUK, Ö., NUHOĞLU, B., HAZAR, A. İ., ÖZKAN, A., BALCI, M. B. C., ÇİLESİZ, N. C. (2022). Comparison of Caveolin-1 and PSA in Prostate Adenocarcinoma. JAREM, Cilt: 9 - Sayı: 3, 121–124. https://ajindex.com/articles/558218

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (7)

Rosai J. (2004) Rosai and Ackerman's Surgical Pathology. (9. baskı) Chapter 18, Male Reproductive System. Elsevier Inc. 1361-411
Epstein JI, Kumar V, Abbas AK, Fausto N. (2005). The Lower Urinary Tract and Male Genital System. (7. baskı) Chapter 21. Robbins and Cotran PathologicDisease. Philadelphia: Elsevier Saunders. 1023-58
Walsh PC, Retik BA, Vaughan ED, Wein AJ. Campbell's urology. 9th ed. Philadelphia: Saunders Co., 2007: 3001-221
Hernandez J, Thompson IM. prostate-specific antigen a review of the validation of the most commoly used cancer biomarker. Cancer 2004; 101: 894-904. [CrossRef] 5. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res 2010; 10: 111-22. [CrossRef] 6. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288: 494-506. [CrossRef] 7. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005; 118: 1493-503 [CrossRef] 8. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin–1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59: 5719-23
Chang WS, Lin SS, Li FJ, Tsai CW, Li LY, Lien CS, et al. Significant association of caveolin-1 (CAV1) genotypes with upper urothelial tract cancer. Anticancer Res 2013; 33: 4907-12
Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, et al. Secreted caveolin–1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-5
Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin–1 secreting LNCaP cells induce tumor growth of caveolin–1 negative LNCaP cells in vivo. Int J Cancer 2008; 122: 520-5. [CrossRef] 12. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23: 9389-404. [CrossRef] 13. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, et al. Tumor cell-secreted caveolin–1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68: 731-9. [CrossRef] 14. Tahir SA, Frolov A, Hayes TG, Mi